A Randomized, Double-blind, Single-center, Placebo-controlled, Dose-escalation Phase Ia Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of DBM-1152A Inhalation Solution in Chinese Healthy Subjects
Latest Information Update: 06 Mar 2026
At a glance
- Drugs DBM 1152A (Primary)
- Indications Bronchiectasis
- Focus Adverse reactions
Most Recent Events
- 06 Mar 2026 New trial record